Targeting NKG2D/NKG2DL axis in multiple myeloma therapy
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
Immune effector cells in patients with multiple myeloma (MM) are at the forefront of many immunotherapy treatments, and several methods have been developed to fully utilise the antitumour potential of immune cells. T and NK cell-derived immune lymphocytes both expressed activating NK receptor group 2 member D(NKG2D). This receptor can identify eight distinct NKG2D ligands (NKG2DL), including major histocompatibility complex class I (MHC) chain-related protein A and B (MICA and MICB). Their binding to NKG2D triggers effector roles in T and NK cells. NKG2DL is polymorphic in MM cells. The decreased expression of NKG2DL on the cell surface is explained by multiple mechanisms of tumour immune escape. In this review, we discuss the mechanisms by which the NKG2D/NKG2DL axis regulates immune effector cells and strategies for promoting NKG2DL expression and inhibiting its release in multiple myeloma and propose therapeutic strategies that increase the expression of NKG2DL in MM cells while enhancing the activation and killing function of NK cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Cytokine & growth factor reviews - 76(2024) vom: 01. Apr., Seite 1-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Zhaoyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Histocompatibility Antigens Class I |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cytogfr.2024.02.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368684172 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368684172 | ||
| 003 | DE-627 | ||
| 005 | 20240408232414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cytogfr.2024.02.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM368684172 | ||
| 035 | |a (NLM)38378397 | ||
| 035 | |a (PII)S1359-6101(24)00011-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Zhaoyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting NKG2D/NKG2DL axis in multiple myeloma therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Immune effector cells in patients with multiple myeloma (MM) are at the forefront of many immunotherapy treatments, and several methods have been developed to fully utilise the antitumour potential of immune cells. T and NK cell-derived immune lymphocytes both expressed activating NK receptor group 2 member D(NKG2D). This receptor can identify eight distinct NKG2D ligands (NKG2DL), including major histocompatibility complex class I (MHC) chain-related protein A and B (MICA and MICB). Their binding to NKG2D triggers effector roles in T and NK cells. NKG2DL is polymorphic in MM cells. The decreased expression of NKG2DL on the cell surface is explained by multiple mechanisms of tumour immune escape. In this review, we discuss the mechanisms by which the NKG2D/NKG2DL axis regulates immune effector cells and strategies for promoting NKG2DL expression and inhibiting its release in multiple myeloma and propose therapeutic strategies that increase the expression of NKG2DL in MM cells while enhancing the activation and killing function of NK cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a NK cell | |
| 650 | 4 | |a NKG2D | |
| 650 | 4 | |a NKG2DL | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 7 | |a NK Cell Lectin-Like Receptor Subfamily K |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class I |2 NLM | |
| 700 | 1 | |a Wang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Hongli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xianghong |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Rong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytokine & growth factor reviews |d 1996 |g 76(2024) vom: 01. Apr., Seite 1-11 |w (DE-627)NLM088318842 |x 1879-0305 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2024 |g day:01 |g month:04 |g pages:1-11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cytogfr.2024.02.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2024 |b 01 |c 04 |h 1-11 | ||